Skip to main content

HypoPARAthyroidism Association Community Webinars

Expert panelist Dr. Dana Pizzuti will provide a development update on Transcon PTH and plans to discuss milestones for the coming year.

Date: February, 7th 8PM EST


Dr. Dana Pizzuti M.D. serves as Senior Vice President, Development Operations and Chief Medical Officer at Ascendis Pharma A/S. Dr. Pizzuti has more than 30 years of pharmaceutical industry experience in clinical development, pharmacovigilance, medical and regulatory Affairs. Prior to joining Ascendis Pharma, Dr. Pizzuti served as Senior Vice President of Regulatory Affairs, Quality and Pharmacovigilance at Theravance Biopharma, Inc., a biotechnology company, from March 2019 to July 2019 and served as Senior Vice President of Regulatory Affairs and Quality at Rigel Pharmaceuticals, a biotechnology company, from June 2017 to March 2019. Prior to Rigel, Dr. Pizzuti served as Vice President of Regulatory Affairs at Gilead Sciences, a pharmaceutical company, from March 2007 to June 2017, where she directly supervised a global regulatory department of more than 500 individuals in 33 countries and was responsible for obtaining marketing authorizations for 15 new drugs in global markets. Prior to Gilead, she served as Vice President of Global Regulatory Affairs for West Coast Pharmaceuticals at Johnson and Johnson and Vice President of Global Pharmacovigilance and Labeling at Bristol-Myers Squibb. For 10 years, she held positions of increasing responsibility in Medical Affairs at Abbott Laboratories, ending her tenure there as Vice President of Global Medical Affairs for the Pharmaceutical Products Division and Abbott International. Dr. Pizzuti began her career in industry at Hoffmann-La Roche. She received her M.D. from New York University and a B.S. in Biology (cum laude) from Yale University